<DOC>
	<DOC>NCT00324324</DOC>
	<brief_summary>RATIONALE: A donor stem cell transplant can lower the body's immune system, making it difficult to fight off infection. Giving antibiotics, such as moxifloxacin, may help prevent bacterial infections in patients who have recently undergone donor stem cell transplant. It is not yet known whether moxifloxacin is more effective than a placebo in preventing bacterial infections in patients who have recently undergone donor stem cell transplant. PURPOSE: This randomized phase III trial is studying moxifloxacin to see how well it works compared with a placebo in preventing bacterial infections in patients who have recently undergone donor stem cell transplant.</brief_summary>
	<brief_title>Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES: Primary - Assess the safety and tolerability of giving prophylactic moxifloxacin hydrochloride during the post-engraftment phase in patients who have undergone allogeneic stem cell transplantation. (Pilot study) - Compare the efficacy, in terms of reducing the incidence of clinically and microbiologically documented bacterial infections, in patients who have undergone allogeneic stem cell transplantation treated with prophylactic moxifloxacin hydrochloride vs placebo during the post-engraftment phase. (Phase III) Secondary - Determine the incidence of clinically and microbiologically documented bacterial infections in these patients. (Pilot study) - Assess the impact of moxifloxacin hydrochloride on the incidence of bacteremia in these patients. (Phase III) - Compare the percentage of time on systemic antibiotics and days hospitalized in patients treated with these regimens. (Phase III) - Compare the incidence of veno-occlusive disease of the liver in patients treated with these regimens. (Phase III) - Compare the incidence and severity of graft-versus-host disease in patients treated with these regimens. (Phase III) - Compare the infection-related mortality and overall mortality of patients treated with these regimens. OUTLINE: This is a pilot study followed by a randomized, double-blind, placebo-controlled, multicenter phase III study. Patients are stratified according to gender and race (white vs. non-white). The first 20 patients are assigned to the pilot study. Patients assigned to the pilot study receive oral moxifloxacin hydrochloride once daily beginning after neutrophil recovery (ANC &gt; 1,500/mm³) from allogeneic stem cell transplantation (ASCT) and continuing until day 100 post-transplantation in the absence of disease progression or unacceptable toxicity. Subsequent patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive oral moxifloxacin hydrochloride once daily beginning after neutrophil recovery (ANC &gt; 1,500/mm³) from ASCT and continuing until day 100 post-transplantation. - Arm II: Patients receive oral placebo once daily beginning after neutrophil recovery (ANC &gt; 1,500/mm³) from ASCT and continuing until day 100 post-transplantation. In both arms, treatment continues in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at day 120 post-transplantation. PROJECTED ACCRUAL: A total of 240 patients will be accrued for this study.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Trophoblastic Neoplasms</mesh_term>
	<mesh_term>Gestational Trophoblastic Disease</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>DISEASE CHARACTERISTICS: Must be planning to undergo or have completed allogeneic stem cell transplantation (ASCT) Must not be undergoing a nonmyeloablative ASCT Must not require antibiotic prophylaxis against bacterial pathogens during the postengraftment phase as per ASCT protocol No known colonization with an antimicrobialresistant organism normally sensitive to quinolones that is known to increase infection incidence (i.e., ciprofloxacinresistant Pseudomonas not allowed; vancomycinresistant Enterococcus and methicillinresistant Staphylococcus aureus allowed) PATIENT CHARACTERISTICS: Life expectancy ≥ 100 days Not pregnant or nursing Fertile patients must use effective contraception Negative pregnancy test No known hypersensitivity to fluoroquinolones No prolonged QTc interval on EKG (i.e., QTc &gt; 440 milliseconds) No uncontrolled hypokalemia PRIOR CONCURRENT THERAPY: See Disease Characteristics No concurrent class IA (e.g., quinidine or procainamide) or class III (e.g., amiodarone or sotalol) antiarrhythmics No concurrent intravenous antibiotics for preenrollment infections except vancomycin, linezolid, dalfopristin, or quinupristin (Synercid®)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>infection</keyword>
	<keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
	<keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
	<keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
	<keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
	<keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia in remission</keyword>
	<keyword>adult acute myeloid leukemia in remission</keyword>
	<keyword>atypical chronic myeloid leukemia, BCR-ABL negative</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>de novo myelodysplastic syndromes</keyword>
	<keyword>disseminated neuroblastoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>poor prognosis metastatic gestational trophoblastic tumor</keyword>
	<keyword>previously treated myelodysplastic syndromes</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>relapsing chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndromes</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
</DOC>